Zastosowanie linagliptyny u chorych na cukrzycę potransplantacyjną. Ocena bezpieczeństwa i skuteczności leczenia na podstawie opisu serii przypadków klinicznych
Abstract
Post-transplantation diabetes (PTDM) is a frequent problem in patients after solid organ transplantation. PTDM is more common in recipients with risk factors of diabetes mellitus, may also be associated with the immunosuppressive regimen used. No specific guidelines for diagnosis and pharmacotherapy of this type of diabetes have been established, therefore those for the treatment of diabetes in general population are followed. The basis of non-pharmacological treatment are diet, weight loss, regular physical exercise. In the choice of antidiabetic therapy in PTDM, additionally graft function and possible drug interactions (especially with immunosuppressive therapy) should be considered. Linagliptin, a dipeptidyl peptidase-4 inhibitor belonging to a relatively new group of diabetic drugs, appears to be an effective and safe drug in monotherapy, but also in combination with other hypoglycemic medications in patients with PTDM.
Keywords: post-transplant diabetes mellituspharmacotherapylinagliptin